Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387135429> ?p ?o ?g. }
Showing items 1 to 93 of
93
with 100 items per page.
- W4387135429 abstract "<h3>Introduction/Background</h3> Standard treatment for patients with first platinum-sensitive relapse of epithelial ovarian cancer (EOC) is based on surgery and second-line systemic chemotherapy. Hyperthermic intra-peritoneal chemotherapy (HIPEC) is still considered an experimental treatment. <h3>Methodology</h3> The CHIPOR international multicentre randomised phase III trial (NCT01376752), conducted in 31 institutions, enrolled patients with a first peritoneal sensitive relapse (platinum-free interval of ≥6 months) of EOC. Patients were treated with 6 cycles of platinum-based chemotherapy, followed by complete debulking cytoreductive surgery. Patients were enrolled after completing chemotherapy and intraoperatively randomly assigned to receive HIPEC (cisplatin 75 mg/m2 at 41°C for 60 min) or not. Randomisation was performed intra-operatively after complete (CC0-CC1) cytoreductive surgery. Stratification factors were centre, surgical outcome (no residual disease vs residual <0.25 cm), chemotherapy-free interval at relapse (6–12 vs 12¬–18 vs >18 months), and planned PARP inhibitor use (yes vs no). The primary endpoint was overall survival (OS). The target sample size was 404 evaluable patients, providing 80% power at 5% alpha after 268 deaths. Secondary endpoints included progression-free survival (PFS), quality of life and pain, safety, and postoperative (≤60 days after surgery) morbidity and mortality. <h3>Results</h3> Between May 11, 2011, and May 14, 2021, 415 patients were randomised. Baseline characteristics were well balanced between treatment arms. At the data cutoff (8 January, 2023, median follow-up 6.2 years), 272 patients (65%) had died. Efficacy results (OS, PFS, time to subsequent therapy, post-operative mortality, morbidity, QoL) will be presented. <h3>Conclusion</h3> HIPEC significantly improves OS and peritoneal PFS of women with first platinum-sensitive relapse of EOC treated with second-line platinum-based CT followed by secondary complete cytoreductive surgery. Ongoing analyses, including patient reported outcome, BRCA status, bevacizumab exposure, and subsequent therapy, will be presented. <h3>Disclosures</h3> LILLY - GLAXOSMITHKLINE" @default.
- W4387135429 created "2023-09-29" @default.
- W4387135429 creator A5003670508 @default.
- W4387135429 creator A5006619822 @default.
- W4387135429 creator A5011011028 @default.
- W4387135429 creator A5020758672 @default.
- W4387135429 creator A5021158894 @default.
- W4387135429 creator A5031036666 @default.
- W4387135429 creator A5031943683 @default.
- W4387135429 creator A5042461515 @default.
- W4387135429 creator A5044830161 @default.
- W4387135429 creator A5045304437 @default.
- W4387135429 creator A5049294891 @default.
- W4387135429 creator A5053409630 @default.
- W4387135429 creator A5053541513 @default.
- W4387135429 creator A5059041310 @default.
- W4387135429 creator A5060565441 @default.
- W4387135429 creator A5072055304 @default.
- W4387135429 creator A5075953565 @default.
- W4387135429 creator A5085026703 @default.
- W4387135429 creator A5091592799 @default.
- W4387135429 creator A5092083661 @default.
- W4387135429 date "2023-09-01" @default.
- W4387135429 modified "2023-10-17" @default.
- W4387135429 title "#876 Hyperthermic intraperitoneal chemotherapy in platinum-sensitive relapsed epithelial ovarian cancer: the chipor randomised phase III trial" @default.
- W4387135429 doi "https://doi.org/10.1136/ijgc-2023-esgo.43" @default.
- W4387135429 hasPublicationYear "2023" @default.
- W4387135429 type Work @default.
- W4387135429 citedByCount "0" @default.
- W4387135429 crossrefType "proceedings-article" @default.
- W4387135429 hasAuthorship W4387135429A5003670508 @default.
- W4387135429 hasAuthorship W4387135429A5006619822 @default.
- W4387135429 hasAuthorship W4387135429A5011011028 @default.
- W4387135429 hasAuthorship W4387135429A5020758672 @default.
- W4387135429 hasAuthorship W4387135429A5021158894 @default.
- W4387135429 hasAuthorship W4387135429A5031036666 @default.
- W4387135429 hasAuthorship W4387135429A5031943683 @default.
- W4387135429 hasAuthorship W4387135429A5042461515 @default.
- W4387135429 hasAuthorship W4387135429A5044830161 @default.
- W4387135429 hasAuthorship W4387135429A5045304437 @default.
- W4387135429 hasAuthorship W4387135429A5049294891 @default.
- W4387135429 hasAuthorship W4387135429A5053409630 @default.
- W4387135429 hasAuthorship W4387135429A5053541513 @default.
- W4387135429 hasAuthorship W4387135429A5059041310 @default.
- W4387135429 hasAuthorship W4387135429A5060565441 @default.
- W4387135429 hasAuthorship W4387135429A5072055304 @default.
- W4387135429 hasAuthorship W4387135429A5075953565 @default.
- W4387135429 hasAuthorship W4387135429A5085026703 @default.
- W4387135429 hasAuthorship W4387135429A5091592799 @default.
- W4387135429 hasAuthorship W4387135429A5092083661 @default.
- W4387135429 hasBestOaLocation W43871354291 @default.
- W4387135429 hasConcept C121608353 @default.
- W4387135429 hasConcept C126322002 @default.
- W4387135429 hasConcept C141071460 @default.
- W4387135429 hasConcept C143998085 @default.
- W4387135429 hasConcept C168563851 @default.
- W4387135429 hasConcept C203092338 @default.
- W4387135429 hasConcept C2776694085 @default.
- W4387135429 hasConcept C2778239845 @default.
- W4387135429 hasConcept C2779458272 @default.
- W4387135429 hasConcept C2780427987 @default.
- W4387135429 hasConcept C2781100745 @default.
- W4387135429 hasConcept C2994223192 @default.
- W4387135429 hasConcept C71924100 @default.
- W4387135429 hasConceptScore W4387135429C121608353 @default.
- W4387135429 hasConceptScore W4387135429C126322002 @default.
- W4387135429 hasConceptScore W4387135429C141071460 @default.
- W4387135429 hasConceptScore W4387135429C143998085 @default.
- W4387135429 hasConceptScore W4387135429C168563851 @default.
- W4387135429 hasConceptScore W4387135429C203092338 @default.
- W4387135429 hasConceptScore W4387135429C2776694085 @default.
- W4387135429 hasConceptScore W4387135429C2778239845 @default.
- W4387135429 hasConceptScore W4387135429C2779458272 @default.
- W4387135429 hasConceptScore W4387135429C2780427987 @default.
- W4387135429 hasConceptScore W4387135429C2781100745 @default.
- W4387135429 hasConceptScore W4387135429C2994223192 @default.
- W4387135429 hasConceptScore W4387135429C71924100 @default.
- W4387135429 hasLocation W43871354291 @default.
- W4387135429 hasOpenAccess W4387135429 @default.
- W4387135429 hasPrimaryLocation W43871354291 @default.
- W4387135429 hasRelatedWork W1720735691 @default.
- W4387135429 hasRelatedWork W2065800215 @default.
- W4387135429 hasRelatedWork W2133480631 @default.
- W4387135429 hasRelatedWork W2367017737 @default.
- W4387135429 hasRelatedWork W3094967310 @default.
- W4387135429 hasRelatedWork W3097676887 @default.
- W4387135429 hasRelatedWork W3102295789 @default.
- W4387135429 hasRelatedWork W363598932 @default.
- W4387135429 hasRelatedWork W4200356714 @default.
- W4387135429 hasRelatedWork W59268075 @default.
- W4387135429 isParatext "false" @default.
- W4387135429 isRetracted "false" @default.
- W4387135429 workType "article" @default.